(TOI) Oncology Institute - Overview

Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NASDAQ (USA) | Market Cap: 308m USD | Total Return: 121.4% in 12m

Medical Care, Clinical Trials, Patient Support
Total Rating 44
Safety 38
Buy Signal -0.93
Medical Care Facilities
Industry Rotation: -13.0
Market Cap: 308M
Avg Turnover: 5.67M USD
ATR: 8.87%
Peers RS (IBD): 77.6
Risk 5d forecast
Volatility92.4%
Rel. Tail Risk-9.61%
Reward TTM
Sharpe Ratio1.20
Alpha135.83
Character TTM
Beta0.538
Beta Downside0.310
Drawdowns 3y
Max DD94.82%
CAGR/Max DD0.70
EPS (Earnings per Share) EPS (Earnings per Share) of TOI over the last years for every Quarter: "2021-03": 0.2, "2021-06": -0.21, "2021-09": -0.02, "2021-12": -0.14, "2022-03": 0.25, "2022-06": -0.09, "2022-09": -0.25, "2022-12": -0.25, "2023-03": -0.33, "2023-06": -0.19, "2023-09": -0.19, "2023-12": -0.21, "2024-03": -0.22, "2024-06": -0.17, "2024-09": -0.1751, "2024-12": -0.143, "2025-03": -0.2085, "2025-06": -0.15, "2025-09": -0.14, "2025-12": -0.0633, "2026-03": 0,
EPS CAGR: 8.30%
EPS Trend: 61.0%
Last SUE: 1.97
Qual. Beats: 1
Revenue Revenue of TOI over the last years for every Quarter: 2021-03: 48.58, 2021-06: 49.844, 2021-09: 52.275, 2021-12: 52.304, 2022-03: 55.161, 2022-06: 60.921, 2022-09: 64.977, 2022-12: 71.424, 2023-03: 76.192, 2023-06: 80.224, 2023-09: 82.035, 2023-12: 85.788, 2024-03: 94.666, 2024-06: 98.578, 2024-09: 99.901, 2024-12: 100.267, 2025-03: 104.406, 2025-06: 119.802, 2025-09: 136.564, 2025-12: 141.957, 2026-03: null,
Rev. CAGR: 28.67%
Rev. Trend: 98.6%
Last SUE: 0.03
Qual. Beats: 0
Warnings

Negative Equity with losses - insolvent profile

Share dilution 1241.0% YoY - potential capital distress

Interest Coverage Ratio -3.2 is critical

Altman Z'' -6.73 < 1.0 - financial distress zone

volatile

Tailwinds

No distinct edge detected

Description: TOI Oncology Institute

The Oncology Institute, Inc. (TOI) is a U.S.-based oncology company. It provides medical oncology services across three segments: Dispensary, Patient Services, and Clinical Trials & Other.

The company offers a comprehensive suite of services, including physician consultations, in-house infusion and dispensary, and clinical trial participation. It also provides supportive care such as radiation, outpatient blood transfusions, and patient support services, including counseling and 24/7 assistance. The oncology sector is characterized by high demand due to an aging population and advancements in cancer treatment.

TOI manages clinical trials for pharmaceutical and medical device companies, and offers specialized programs like palliative care and stem cell transplants. This business model often involves partnerships with pharmaceutical companies and research institutions.

The company, founded in 2007 and headquartered in Cerritos, California, primarily serves adult and senior cancer patients.

Further research on ValueRay could provide deeper insights into TOIs financial performance and market position.

Headlines to Watch Out For
  • Patient Services revenue growth drives profitability
  • Dispensary segment margins impact overall performance
  • Clinical Trials segment expands revenue opportunities
  • Healthcare policy changes introduce regulatory risk
  • Physician and staffing costs influence operational efficiency
Piotroski VR‑10 (Strict) 2.5
Net Income: -60.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.17 > 0.02 and ΔFCF/TA 0.68 > 1.0
NWC/Revenue: 8.31% < 20% (prev 15.30%; Δ -6.99% < -1%)
CFO/TA -0.15 > 3% & CFO -24.6m > Net Income -60.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.59 > 1.5 & < 3
Outstanding Shares: last quarter (1.01b) vs 12m ago 1.24k% < -2%
Gross Margin: 13.82% > 18% (prev 0.14%; Δ 1.37k% > 0.5%)
Asset Turnover: 298.0% > 50% (prev 227.8%; Δ 70.25% > 0%)
Interest Coverage Ratio: -3.20 > 6 (EBITDA TTM -29.1m / Interest Expense TTM 11.3m)
Altman Z'' -6.73
A: 0.25 (Total Current Assets 112.7m - Total Current Liabilities 71.0m) / Total Assets 164.7m
B: -1.65 (Retained Earnings -271.4m / Total Assets 164.7m)
C: -0.21 (EBIT TTM -36.1m / Avg Total Assets 168.7m)
D: -1.50 (Book Value of Equity -271.4m / Total Liabilities 180.4m)
Altman-Z'' Score: -6.73 = D
Beneish M -3.17
DSRI: 0.95 (Receivables 59.3m/48.7m, Revenue 502.7m/393.4m)
GMI: 0.99 (GM 13.82% / 13.73%)
AQI: 0.87 (AQ_t 0.11 / AQ_t-1 0.13)
SGI: 1.28 (Revenue 502.7m / 393.4m)
TATA: -0.22 (NI -60.6m - CFO -24.6m) / TA 164.7m)
Beneish M-Score: -3.17 (Cap -4..+1) = AA
What is the price of TOI shares? As of April 07, 2026, the stock is trading at USD 3.12 with a total of 640,189 shares traded.
Over the past week, the price has changed by +13.43%, over one month by +15.47%, over three months by -22.28% and over the past year by +121.38%.
Is TOI a buy, sell or hold? Oncology Institute has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy TOI.
  • StrongBuy: 1
  • Buy: 0
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the TOI price?
Analysts Target Price 7 124.4%
Oncology Institute (TOI) - Fundamental Data Overview as of 06 April 2026
P/S = 0.6134
P/B = 74.3433
Revenue TTM = 502.7m USD
EBIT TTM = -36.1m USD
EBITDA TTM = -29.1m USD
Long Term Debt = 77.4m USD (from longTermDebt, last quarter)
Short Term Debt = 7.16m USD (from shortTermDebt, last quarter)
Debt = 26.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -7.28m USD (from netDebt column, last quarter)
Enterprise Value = 301.1m USD (308.4m + Debt 26.3m - CCE 33.6m)
Interest Coverage Ratio = -3.20 (Ebit TTM -36.1m / Interest Expense TTM 11.3m)
EV/FCF = -10.84x (Enterprise Value 301.1m / FCF TTM -27.8m)
FCF Yield = -9.23% (FCF TTM -27.8m / Enterprise Value 301.1m)
FCF Margin = -5.53% (FCF TTM -27.8m / Revenue TTM 502.7m)
Net Margin = -12.06% (Net Income TTM -60.6m / Revenue TTM 502.7m)
Gross Margin = 13.82% ((Revenue TTM 502.7m - Cost of Revenue TTM 433.2m) / Revenue TTM)
Gross Margin QoQ = 11.14% (prev 13.85%)
Tobins Q-Ratio = 1.83 (Enterprise Value 301.1m / Total Assets 164.7m)
Interest Expense / Debt = 7.29% (Interest Expense 1.92m / Debt 26.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -28.5m (EBIT -36.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.59 (Total Current Assets 112.7m / Total Current Liabilities 71.0m)
 Debt / Equity = -1.67 (negative equity) (Debt 26.3m / totalStockholderEquity, last quarter -15.7m)
 Debt / EBITDA = 0.25 (negative EBITDA) (Net Debt -7.28m / EBITDA -29.1m)
 Debt / FCF = 0.26 (negative FCF - burning cash) (Net Debt -7.28m / FCF TTM -27.8m)
 Total Stockholder Equity = -7.98m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.93% (Net Income -60.6m / Total Assets 164.7m)
 RoE = 759.7% (negative equity) (Net Income TTM -60.6m / Total Stockholder Equity -7.98m)
 RoCE = -51.98% (EBIT -36.1m / Capital Employed (Equity -7.98m + L.T.Debt 77.4m))
 RoIC = -42.14% (negative operating profit) (NOPAT -28.5m / Invested Capital 67.7m)
 WACC = 7.71% (E(308.4m)/V(334.7m) * Re(7.88%) + D(26.3m)/V(334.7m) * Rd(7.29%) * (1-Tc(0.21)))
Discount Rate = 7.88% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 271.6%
 [DCF] Fair Price = unknown (Cash Flow -27.8m)
 EPS Correlation: 60.95 | EPS CAGR: 8.30% | SUE: 1.97 | # QB: 1
Revenue Correlation: 98.62 | Revenue CAGR: 28.67% | SUE: 0.03 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.07 | Chg7d=+0.016 | Chg30d=+0.016 | Revisions Net=+1 | Analysts=4
EPS current Year (2026-12-31): EPS=-0.23 | Chg7d=+0.070 | Chg30d=+0.070 | Revisions Net=+2 | Growth EPS=+57.9% | Growth Revenue=+28.9%
EPS next Year (2027-12-31): EPS=-0.08 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+64.8% | Growth Revenue=+25.8%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle